Trial Profile
Phase II/III clinical trial of TO-206 - Evaluation of efficacy and safety in patients with Japanese cedar pollinosis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Japanese cedar pollen allergy immunotherapy ALK Abello/Torii Pharmaceutical (Primary)
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Torii Pharmaceutical
- 24 Jun 2019 Results presented in an ALK-Abello media release.
- 24 Jun 2019 According to an ALK-Abello media release, the Canadian regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for review by the relevant health authorities. The data used in the filing include results from the Phase III clinical trial finalised in 2017.
- 27 Sep 2017 According to ALK's media release, Japan's Ministry of Health, Labour and Welfare has approved the New Drug Application submitted by its partner Torii Pharmaceutical Co Ltd, for the Japanese cedar sublingual allergy immunotherapy (SLIT) tablet, which will be branded CEDARCURE.